Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 USD | -1.23% | -8.05% | +13.48% |
Mar. 15 | RBC Cuts Price Target on aTyr Pharma to $16 From $19, Keeps Outperform Rating, Speculative Risk Qualifier | MT |
Mar. 14 | Transcript : ATyr Pharma, Inc., Q4 2023 Earnings Call, Mar 14, 2024 |
Business Summary
Number of employees: 58
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Innovative Medicines
100.0
%
| 10 | 100.0 % | 0 | 100.0 % | -96.60% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 10 | 100.0 % | 0 | 100.0 % | -96.60% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jill Broadfoot
DFI | Director of Finance/CFO | 63 | 18-07-29 |
Lisa Carey
CTO | Chief Tech/Sci/R&D Officer | - | 15-05-31 |
Ashlee Dunston
IRC | Investor Relations Contact | - | 20-03-31 |
Peter Villiger
PRN | Corporate Officer/Principal | - | 16-04-30 |
Human Resources Officer | - | 21-12-23 | |
General Counsel | - | 21-10-05 | |
Leslie Nangle
PRN | Corporate Officer/Principal | - | - |
Nancy Krueger
LAW | General Counsel | 56 | 14-09-30 |
Andrew B. Cubitt
PRN | Corporate Officer/Principal | - | 11-08-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Schimmel
FOU | Founder | 83 | 05-09-07 |
Tim Coughlin
CHM | Chairman | 57 | 17-04-09 |
John K. Clarke
BRD | Director/Board Member | 70 | 05-08-31 |
Sara L. Zaknoen
BRD | Director/Board Member | 65 | 21-05-24 |
Sanjay Shukla
CEO | Chief Executive Officer | 52 | 16-03-29 |
Jane Gross
BRD | Director/Board Member | 67 | 19-06-27 |
Svetlana Lucas
BRD | Director/Board Member | 52 | 19-06-27 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,940,841 | 66,158,839 ( 97.38 %) | 0 | 97.38 % |
Company contact information
aTyr Pharma, Inc.
10240 Sorrento Valley Road Suite 300
92121, San Diego
+858 731 8389
http://www.atyrpharma.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.48% | 110M | |
-1.42% | 41.35B | |
+42.15% | 40.38B | |
+1.97% | 39.05B | |
-14.19% | 26.67B | |
+1.82% | 24.07B | |
-24.55% | 18.36B | |
-4.07% | 11.68B | |
+21.36% | 11.6B | |
+8.20% | 11.15B |
- Stock Market
- Equities
- LIFE Stock
- Company aTyr Pharma, Inc.